Generic Aggrastat Availability
AGGRASTAT (tirofiban hydrochloride - injectable;injection)
Approval date: May 14, 1998
Strength(s): EQ 12.5MG BASE/50ML (EQ 0.25MG BASE/ML), EQ 25MG BASE/500ML (EQ 0.05MG BASE/ML)
Approval date: April 20, 2000
Strength(s): EQ 12.5MG BASE/250ML (EQ 0.05MG BASE/ML) [RLD]
Approval date: May 17, 2002
Strength(s): EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML) [RLD]
AGGRASTAT (tirofiban hydrochloride - solution;injection)
Approval date: August 31, 2016
Strength(s): EQ 3.75MG BASE/15ML (EQ 0.25MG BASE/ML) [RLD]
Has a generic version of Aggrastat been approved?
No. There is currently no therapeutically equivalent version of Aggrastat available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Aggrastat. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Platelet aggregation inhibition using low molecular weight heparin in combination with a GP IIb/IIIa antagonist
Issued: October 24, 2000
Inventor(s): Cook; Jacquelynn J. & Gould; Robert J. & Sax; Frederic L.
Assignee(s): Merck & Co., Inc.
A method for inhibiting platelet aggregation in a mammal comprising administering to the mammal a safe and therapeutically effective amount of a GPIIb/IIIa receptor antagonist or a pharmaceutically acceptable salt thereof and a safe and therapeutically effective amount of low molecular weight heparin. A method for inhibiting platelet aggregation in a mammal comprising administering to the mammal a safe and therapeutically effective amount of (2-S-(n-butylsulfonylamino)-3[4-(piperidin-4-yl)butyloxyphenyl]-propionic acid or a pharmaceutically acceptable salt thereof and a safe and therapeutically effective amount of low molecular weight heparin.
Patent expiration dates:
- January 29, 2019
- January 29, 2019✓
- January 29, 2019
Method for inhibiting platelet aggregation
Issued: August 3, 2004
Inventor(s): Peter M.; DiBattiste & David; Schneider
Assignee(s): Artery LLC
A method for inhibiting platelet aggregation in a patient in need thereof, comprising 1) administering to the patient a bolus injection of an active drug, in an amount of about 25 &mgr;g/kg, and 2) administering to the patient, after the bolus injection, an intravenous infusion for a period of between about 12 hours and about 72 hours, of the active drug, in an amount of about 0.15 &mgr;g/kg/min, wherein the active drug is tirofiban or a salt thereof.
Patent expiration dates:
- May 1, 2023✓
- May 1, 2023
More about Aggrastat (tirofiban)
- Aggrastat Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- Support Group
- Pricing & Coupons
- En Español
- 0 Reviews
- Drug class: glycoprotein platelet inhibitors
Related treatment guides
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|